Related Experiment Video

Updated: May 9, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post-DAA Management

Shen-Shong Chang1,2,3,4, Ching-Hsuan Liu5, Shu-Yen Chan6

  • 1Division of Gastroenterology, Taipei City Hospital Yang-Ming Branch, Taipei, Taiwan.

Journal of Medical Virology
|May 8, 2026
PubMed

Insights

Hepatitis C virus (HCV) infection is linked to type 2 diabetes mellitus (T2DM) through various mechanisms. Direct-acting antiviral (DAA) therapies can improve insulin resistance and reduce diabetes risk in HCV patients.

Area of Science:

  • Hepatology
  • Endocrinology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection is a significant global health issue.
  • HCV is associated with metabolic disorders, especially type 2 diabetes mellitus (T2DM), increasing liver disease complications and mortality.
  • HCV infection contributes to insulin resistance (IR) via viral proteins, oxidative stress, and impaired metabolism.

Purpose of the Study:

  • To review the mechanistic links between HCV infection and T2DM.
  • To synthesize epidemiological and clinical evidence on HCV-associated metabolic disease.
  • To guide integrated management strategies for HCV and T2DM.

Main Methods:

  • Literature review of epidemiological studies.
  • Analysis of mechanistic pathways linking HCV to insulin resistance.
  • Evaluation of clinical outcomes following direct-acting antiviral (DAA) therapy.

Main Results:

  • HCV infection significantly increases the prevalence of T2DM and insulin resistance.
  • Multiple viral and host factors mediate HCV-induced IR and pancreatic dysfunction.
  • DAA therapy improves insulin sensitivity, reduces diabetes incidence, and lowers cardiovascular risk in HCV patients.
  • T2DM exacerbates HCV-related liver fibrosis, HCC risk, and mortality.

Conclusions:

  • HCV infection and T2DM have a detrimental bidirectional relationship.
  • Eradication of HCV with DAAs offers significant metabolic benefits.
  • Integrated management of viral clearance and glycemic control is crucial for improving patient outcomes.

Keywords:
direct‐acting antiviralshepatitis C virusinsulin resistancetype 2 diabetes mellitus

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...